Rpl13a small nucleolar RNAs regulate systemic glucose metabolism

Jiyeon Lee,1 Alexis N. Harris,1 Christopher L. Holley,1 Jana Mahadevan,2 Kelly D. Pyles,1 Zeno Lavagnino,3 David E. Scherrer,1 Hideji Fujiwara,1 Rohini Sidhu,1 Jessie Zhang,1 Stanley Ching-Cheng Huang,4 David W. Piston,1 Maria S. Remedi,2 Fumihiko Urano,2 Daniel S. Ory,1 and Jean E. Schaffer1

1Diabetic Cardiovascular Disease Center and Department of Internal Medicine, 2Department of Internal Medicine, 3Department of Cell Biology and Physiology and Department of Internal Medicine, and 4Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.

Small nucleolar RNAs (snoRNAs) are non-coding RNAs that form ribonucleoproteins to guide covalent modifications of ribosomal and small nuclear RNAs in the nucleus. Recent studies have also uncovered additional non-canonical roles for snoRNAs. However, the physiological contributions of these small RNAs are largely unknown. Here, we selectively deleted four snoRNAs encoded within the introns of the ribosomal protein L13a (Rpl13a) locus in a mouse model. Loss of Rpl13a snoRNAs altered mitochondrial metabolism and lowered reactive oxygen species tone, leading to increased glucose-stimulated insulin secretion from pancreatic islets and enhanced systemic glucose tolerance. Islets from mice lacking Rpl13a snoRNAs demonstrated blunted oxidative stress responses. Furthermore, these mice were protected against diabetogenic stimuli that cause oxidative stress damage to islets. Our study illuminates a previously unrecognized role for snoRNAs in metabolic regulation.

Introduction

Box C/D snoRNAs are short noncoding RNAs containing conserved C and D box consensus motifs that form ribonucleoproteins with NOP56, NOP58, 15.5 kDa, and the methyltransferase fibrillarin (1). These ribonucleoproteins localize to nucleoli, where their canonical function is to serve as guides to target specific sites on ribosomal RNAs (rRNAs) or small nuclear RNAs (snRNAs) for 2′-O-methylation through a short stretch of antisense complementarity (10–21 nucleotides). In vertebrates, this function has been demonstrated experimentally for some box C/D snoRNAs and is predicted for others. The observation that animals homozygous for knockout of fibrillarin are inviable indicates that functions of box C/D snoRNAs as a class are essential for normal development (2).

Genetic studies have suggested an expanding functional repertoire for snoRNAs beyond their well-established roles in modification and processing of rRNAs and snRNAs (3). Dysregulated snoRNA expression has been associated with altered splicing in the developmental syndromes, Prader-Willi and tetralogy of Fallot (4, 5), and snoRNAs U50, ACA11, and ACA42 have been shown to modulate tumor proliferation in vivo (6–9). Nonetheless, the physiological consequences of perturbation of expression of most mammalian snoRNAs remain unexplored, and no animal models exist with selective and complete loss of function for any snoRNAs.

Our laboratory’s studies have demonstrated that box C/D snoRNAs encoded by introns of the Rpl13a locus function as critical mediators of cell death in response to metabolic and oxidative stress in cultured cells (10–12). The observations that this role can be dissociated from changes in the 2′-O-methylation status of predicted ribosomal RNA targets and that the Rpl13a snoRNAs accumulate in the cytosol during oxidative stress suggest that the Rpl13a snoRNAs may function through noncanonical mechanisms. The goal of this study was to determine the physiological role of these noncoding RNAs.

Results

Generation of Rpl13a-snoless mice. Our previous work demonstrated a critical role for box C/D snoRNAs U32a, U33, U34, and U35a, embedded within 4 introns of the Rpl13a locus (Figure 1A), in the cellular response to lipotoxic and oxidative stress (10). The observation that loss of function of the individual snoRNAs in cultured cells is not sufficient to confer resistance to metabolic stress suggests that these 4 snoRNAs function in concert in stress response pathways. Therefore, to probe the long-term physiological consequences of loss of function of Rpl13a snoRNAs, we generated a model with simultaneous loss of all 4 box C/D snoRNAs encoded in this locus. Since deletion of the RPL13a protein in Drosophila is embryonic lethal (13), our goal was to selectively modify 4 snoRNA-hosting introns without perturbing expression of the exon-encoded ribosomal protein. This was accomplished using a single recombination event to replace the locus with an allele from which the snoRNAs were selectively deleted (Figure 1, A–C, and Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI88069DS1). No known regulatory regions overlap with these 4 snoRNAs, and these intronic sequences are relatively depleted of H3K27 histone marks that are often found near regulatory regions.

Homozygous Rpl13a snoRNA loss-of-function mice (referred to hereafter in text as Rpl13a-snoless and in figures as −/−) were live-born at normal Mendelian ratios, were fertile, and displayed no overt pathophysiological phenotype under standard housing,
feeding, and breeding conditions. Body weight and body composition were indistinguishable between Rpl13a-snoless and WT mice (Supplemental Figure 2, A and B). The Rpl13a-snoless mice were deficient in expression of the 4 intronic snoRNAs from this locus, but Rpl13a mRNA and protein levels were indistinguishable from those of WT controls (Figure 2, A and B), and expression of other snoRNAs was unchanged (Supplemental Figure 2C). Fibroblasts from Rpl13a-snoless embryos (MEFs) had significantly lower levels of cellular superoxide and hydrogen peroxide under normal growth conditions (Figure 2, C and D). Furthermore, following brief exposure to exogenous hydrogen peroxide, Rpl13a-snoless MEFs had diminished ability to amplify ROS. Lower basal ROS tone and resistance to ROS stimulation are consistent with the phenotype of the previously reported mutant Chinese hamster ovary cell line, in which decreased expression of the Rpl13a snoRNAs caused diminished oxidative stress responses (10).

Altered glucose homeostasis in Rpl13a-snoless mice. ROS participate in physiologic signaling cascades that regulate insulin secretion. Therefore, we assessed systemic glucose metabolism in Rpl13a-snoless mice. Fasting plasma glucose and insulin levels were indistinguishable between WT and Rpl13a-snoless mice; however, glucose tolerance test (GTT) revealed enhanced glucose tolerance with lower peak glucose excursion and decreased AUC following an intraperitoneal glucose bolus (Figure 3A). To understand the cause of these changes in glucose metabolism, we used a sensitive Singulex single molecule tracking method to quantify fasting serum insulin and insulin levels at the 30-minute time point of the GTT, the point at which the greatest difference in serum glucose was observed between the genotypes. Serum insulin was significantly increased in Rpl13a-snoless mice at the 30-minute time point (Figure 3B), implicating enhanced release of insulin into the circulation in response to a glucose challenge as the cause of improved glucose tolerance. By contrast, glucose levels during insulin tolerance test (ITT) were similar between the genotypes (Figure 3C), further suggesting that the lower peak glucose excursion resulted not from alterations in peripheral insulin sensitivity, but rather from a difference in insulin secretion.

Rpl13a-snoless islets have enhanced insulin secretion. To investigate the physiological basis of increased insulin levels following a glucose challenge, we examined pancreatic tissue of 8-week-old WT and Rpl13a-snoless animals. β Cell mass as determined by morphometric analysis was indistinguishable between the genotypes (Figure 4A). Protein and insulin content of isolated islets were also not different between WT and Rpl13a-snoless mice (Figure 4, B and C). Nonetheless, consistent with enhanced insulin secretion and glucose tolerance in vivo, Rpl13a-snoless islets had a 51% increase in glucose-stimulated insulin secretion (GSIS; Figure 4D). Similar insulin release from islets of the two genotypes in response to potassium chloride and glibenclamide indicated that the secretory machinery downstream of the K ATP channel is intact in Rpl13a-snoless islets (Figure 4E). Consistent with increased insulin secretion at stimulatory glucose concentrations, Rpl13a-snoless islets demonstrated increased calcium oscillations, and these differences were greatest at 8 mM and 16 mM glucose (Figure 4F and Supplemental Figure 3). We confirmed that Rpl13a snoRNAs are expressed in WT, but not Rpl13a-snoless, islets (Figure 4F and Supplemental Figure 3). Together, these findings suggest that enhanced glucose tolerance in Rpl13a-snoless mice results from greater islet insulin secretion following glucose challenge.

Increased mitochondrial leak and lower ROS in Rpl13a-snoless islets. Glucose stimulates insulin secretion through its metabolism to produce “metabolic coupling factors” that regulate the cellular machinery for insulin secretion (14). To assess islet glucose metabolism and mitochondrial function, we quantified oxygen consumption rates (OCR) in isolated WT and Rpl13a-snoless islets at baseline and following serial addition of modulators that target specific components of the electron transport chain. At 3 mM glucose, basal and maximal respiration, ATP production, and spare respiratory capacity were comparable between the genotypes, with a large

Figure 1. Generation of mice lacking Rpl13a snoRNAs. (A) WT locus and targeting construct (−/−) with exons in black and intronic snoRNAs in gray rectangles. (B) Representative Southern blot from F1 (+/−) and WT offspring (n = 5 experiments) using probe indicated in A. (C) Primers (straight arrows) and predicted size (nucleotides) of genotyping PCR products, above. Representative agarose gel of PCR products from tail DNA is shown below (n > 10 experiments).
Figure 2. Rpl13a-snoless mice demonstrate lower ROS tone. (A) RT-qPCR-quantified expression of Rpl13a snoRNAs and mRNA (relative to Rplp0) in WT and Rpl13a-snoless (–/-) fibroblasts. Mean ± SEM for n = 3 independent experiments. (B) Representative Western blot of Rpl13a protein in embryos (n = 4 mice/genotype). (C) MitoSOX staining of embryonic fibroblasts. Mean fluorescence of 104 cells/sample ± SEM for n = 4 independent experiments. (D) DCF staining of embryonic fibroblasts under basal growth conditions and following exposure to 100 μM H2O2 for 10 minutes. n = 3 independent experiments. * P < 0.005 for –/– vs. WT determined by unpaired t test. rel, relative.

ROS production. Given that ROS can function to inhibit GSIS (20, 21), our findings suggest a model in which enhanced mitochondrial proton leak and the resulting lower ROS in Rpl13a-snoless islets leads to greater insulin secretion.

To gain further mechanistic insight into these observations, we carried out RNAseq analysis of Rpl13a-snoless and WT islets. We observed 2-fold or greater differences in the expression of only 6 genes, none of which encode a mitochondrial protein or is known to have direct effects on the response to ROS (Supplemental Tables 1 and 2). None is predicted bioinformatically to have strong binding sites for U32a, U33, U24, or U35a (22). Our findings suggest these 6 genes are unlikely to be direct targets of the Rpl13a snoRNAs, and effects of Rpl13a snoRNAs on gene expression may be post-transcriptional.

Rpl13a-snoless mice are resistant to diabetogenic stimuli. ROS have also been implicated in the pathogenesis of diabetes in animal models and in humans (23–27). The enhanced ROS tolerance of Rpl13a-snoless islets suggested that Rpl13a-snoless mice would have improved responses to diabetogenic stimuli. We therefore examined the susceptibility of Rpl13a-snoless mice to treatment with low dose streptozotocin, an antibiotic known to cause β-cell oxidative stress and cell death (28). After administration of streptozotocin or sodium citrate as control, mice were followed for an additional 8 weeks. Hyperglycemia was less severe in streptozotocin-treated Rpl13a-snoless mice compared with WT mice (Figure 7A). GTT performed 8 weeks after streptozotocin treatment revealed lower blood glucose in Rpl13a-snoless mice at each time point (Figure 7B). In sodium citrate–treated mice, fasting blood glucose was indistinguishable between the genotypes, with persistence of improved glucose tolerance in Rpl13a-snoless mice at 16 weeks of age (Supplemental Figure 5). To gain insight into the mechanism of this protection, we harvested pancreas tissue from an independent cohort of animals 5 days after streptozotocin treatment. While markers of inflammation and β cell replication were indistinguishable between the genotypes (Supplemental Figure 5), streptozotocin-induced accumulation of the oxidatively modified lipids 4-hydroxynonenal and 3β,5α,6β-cholestane triol (triol) was prevented in Rpl13a-snoless mice (Figure 7, C and D). Furthermore, TUNEL staining of insulin-positive β cells was decreased by 50% in Rpl13a-snoless animals.
compared with WT controls (Figure 7E). This indicates that Rpl13a snoRNAs function in propagation of oxidative stress in the pancreas and in β cell apoptosis in response to streptozotocin.

We further evaluated the effect of loss of Rpl13a snoRNAs in other murine models of diabetes. In the Akita model of diabetes, the Ins2<sup>+<sup>c<sup>−<sup>y<sup> allele causes endoplasmic reticulum and oxidative stress, leading to β cell apoptosis and diabetes (29, 30). Loss of function of the Rpl13a snoRNAs decreased the degree of hyperglycemia in both male and female mice carrying the Ins2<sup>+<sup>c<sup>−<sup>y<sup> allele (Figure 7F). In the non-obese diabetic (NOD) model, oxidative damage in pancreatic β cells, β cell destruction, and the development of diabetes are mitigated by treatment with inhibitors of ROS-producing enzymes, treatment with chemical ROS scavengers, or β cell-specific overexpression of antioxidants, independent of immune cell infiltration into islets (24, 31, 32). Cross of the Rpl13a-snoless alleles into the NOD strain revealed that loss of the snoRNAs was also protective against the development of hyperglycemia in the NOD background (Figure 7G). Taken together, our findings provide evidence that the Rpl13a snoRNAs contribute to hyperglycemia in 3 independent murine models of diabetogenesis.

Discussion

Here, we identified noncanonical metabolic roles for box C/D snoRNAs in the physiological function and pathophysiological responses of β cells. Although broad loss of box C/D snoRNA-directed 2′-O-methyl modifications of ribosomal RNAs that results from fibrillinar knockout is embryonic lethal (2), we demonstrate that selective loss of 4 snoRNAs in the Rpl13a-snoless model is compatible with normal murine development. Unexpectedly, this model revealed a role for Rpl13a-snoRNAs in regulation of islet responses to metabolic stress that impacts whole body glucose homeostasis. Furthermore, the snoRNAs also modulate the response to stimuli that damage islets through oxidative stress, thereby impacting diabetes susceptibility. Together, these results establish that box C/D snoRNAs from the Rpl13a locus have non-canonical functions in pancreatic β cells beyond a housekeeping role in the biosynthesis of ribosomal RNAs. Our findings provide new insights into islet biology, systemic metabolic homeostasis, and the pathophysiology of diabetes.

Loss of the Rpl13a-snoless mice in this model led to enhanced GSIS in isolated pancreatic islets. Loss of the snoRNAs was also associated with increased mitochondrial proton leak, lower ROS tone, and diminished amplification of cellular ROS in response to high glucose, as well as chemicals that more directly induce ROS. Uncoupled respiration has been shown to decrease mitochondrial hydrogen peroxide production during metabolic challenge (17, 18), providing a precedent for our observations of increased leak and decreased ROS in the islets. Furthermore, high levels of ROS and oxidative stress are known to inhibit β cell release of insulin (19–21, 33). Our findings suggest that under stimulatory glucose conditions, Rpl13a-snoless islets escape this inhibition, because they maintain lower oxidative tone. Together, our results suggest that in the Rpl13a-snoless model, mitochondrial proton leak leads to lower islet ROS and greater insulin secretion in the face of metabolic challenge, with resulting enhanced efficiency of systemic glucose metabolism.

The relationship between ROS and insulin secretion from pancreatic β cells is complex. These specialized cells are characterized by low-level expression of many antioxidant enzymes yet support high-level synthesis of a secreted protein that must undergo proper folding and disulfide bond formation in the endoplasmic reticulum, a process that is exquisitely sensitive to changes in cellular redox state (34–36) Furthermore, ROS function in several different ways to regulate insulin secretion. Findings that stimulatory glucose levels induce mitochondrial ROS, and antioxidants that blunt this ROS inhibit GSIS, support a role for ROS as a stimulus required for GSIS (20, 37). On the other hand, high levels of ROS that induce oxidative stress impair GSIS, and loss of function of ROS-producing enzymes or scavenging of ROS potentiates GSIS (20, 21, 33). Specifically, high levels of ROS have been proposed to inhibit insulin granule exocytosis and to interfere with stimulus-secretion coupling in β cells (38, 39). Our observations of lowered provoked ROS and improved GSIS in Rpl13a-snoless islets, without a change in antioxidant potential, suggest that the major impact of loss of these noncoding RNAs is on production of ROS species that serve to inhibit insulin secretion.

Rpl13a-snoless mice have germline disruption of Rpl13a snoRNAs. Thus, although ITT responses were comparable between the genotypes, effects on systemic glucose homeostasis from tissues other than islets cannot be formally excluded. Given our goal of precisely removing 4 distinct intronic sequences (ranging from 66 to 89 nucleotides in length) within a genomic space of 2.8 kb, without disturbing expression of the host protein-coding sequences, we chose to knock in a “snoless” allele. Neither Cre-lox technology nor CRISPR approaches would have been feasible for generation of the 4 simultaneous conditional mutations, as this would have required generation and interbreeding of 4 distinct knockout lines to achieve tissue specificity. In our knockin model, howev-
The Journal of Clinical Investigation

Figure 4. Rpl13a-snoless islets demonstrate enhanced glucose-stimulated insulin secretion. (A) Representative insulin-stained pancreas sections with morphometric quantification of β cell mass for WT and Rpl13a-snoless (−/−) mice (n = 4 mice/genotype). Mean ± SEM; n = 4 mice/genotype; scale bars: 25 μm. (B) Mean islet protein content (+SEM) quantified in 8 mice/genotype (10 islets/mouse) obtained from 3 independent experiments. (C) Mean islet insulin content (+SEM) quantified in 12 mice/genotype (10 islets/mouse) obtained from 3 independent experiments. (D) Mean islet insulin secretion (+SEM) in response to low and high glucose quantified in a minimum of 9 mice/genotype over 3 independent experiments. (E) Mean islet insulin secretion (+SEM) in response to 30 mM KCl and 1 μM glibenclamide quantified in 3–4 mice/genotype over 3 independent experiments. (F) Changes in Fluo-4–quantiﬁed calcium activity of islets relative to basal, expressed as ΔF/Δt, for differing glucose concentrations. Data from 20 independent cells from 4 mice/genotype. (G) RT-qPCR quantiﬁed expression of Rpl13a snoRNAs and mRNA in islets (relative to Rplp0). n = 3 independent islet preparations/genotype. **P < 0.001; *P < 0.05; for −/− vs. WT determined by unpaired t test.
en that snoRNAs can be targeted for antisense knockdown, our findings suggest that molecular therapies could be designed to target these noncoding RNAs.

Methods

Mice. To generate mice lacking all 4 Rpl13a snoRNAs, we created a targeting vector containing the Rpl13a sequence between exons 1 and 8 with a loxp-flanked neomycin phosphotransferase (NEO) cassette in intron 1, and lacking the U32a, U33, U34, and U35a snoRNAs in introns 2, 4, 5, and 6, respectively. The construct was electroporated into 129S5/SvEv ES cells. ES cells with the correct homologous recombination event were selected by neomycin resistance, PCR, and Southern blot analysis. ES clones with normal karyotype were microinjected into 129S5/SvEv/FVB blastocysts that were implanted into pseudopregnant females. F1 progeny from the resulting chimeras were tested for the presence of the Rpl13a locus by Southern blot analysis. ES clones with normal karyotype were microinjected into 129S5/SvEv/FVB blastocysts that were implanted into pseudopregnant females.

Supplemental Table 3 for genotyping primers. Mice generated from these mice were backcrossed into the FVB/N strain more than 10 generations. See Methods for genotyping primers. Mice generated from the Washington University Diabetes Research Center. Speed Con- genics (49) was used to move the Rpl13a-snoless allele onto the NOD background strain, using a marker-assisted breeding strategy. At each generation, multiple offspring were analyzed for genomic single nucleotide polymorphisms to select subsequent breeders with the highest percentage of NOD. After 6 generations, animals were >98.2% NOD.

Figure 5. Increased mitochondrial leak in Rpl13a-snoless islets. (A) OCR of WT and –/– islets at 3 mM glucose with injection of oligomycin (OM), FCCP, and rotenone and antimycin A (Rot/AntA). Data points in line graphs (left) represent mean values (±SEM) from 3 independent experiments in which islets pooled by genotype were used to generate a total of 12( WT) or 8 (–/–) technical replicates from n = 13 WT and n = 14 –/– animals. Graphs as in A. (C) OCR of WT and –/– islets initially maintained at 3 mM glucose; this was changed at the time indicated to 20 mM glucose. Data points represent mean values (±SEM) from 3 independent experiments in which islets pooled by genotype generated 12 (WT) or 8 (–/–) technical replicates from n = 15 WT and n = 10 –/– animals. *P < 0.05 for –/– vs. WT; **P < 0.01 for –/– vs. WT determined by unpaired t test.
bodies (Jackson ImmunoResearch Laboratories) and Western Light-
ing Plus-ECL (PerkinElmer Life Sciences) reagent. Images were
digitally captured using a Bio-Rad ChemiDoc MP and analyzed with
Bio-Rad Image Lab software.

Islet isolation. Pancreases were inflated with ice-cold collagenase
(Sigma-Aldrich) buffer (0.45 mg/ml collagenase in HBSS without
Ca²⁺) and digested at 37°C. Islets were collected after sequential wash-
es and incubated overnight in RPMI media (with 10% FBS and 2 mM
L-glutamine) until use (51). Islets of equal size were hand picked to
generate 3–5 technical replicates (measures, wells) for all experiments.
Very large and very small islets were excluded. Results are reported for
a minimum of 3 independent experiments.

Insulin secretion assay. Hand-picked islets were distributed into
0.4-μm Transwells of a 24-well plate containing Krebs-Ringer buf-
fer (KRB) without glucose. After washing twice in 2.8 mM glucose,
islets were sequentially incubated in 5.6 mM and 16.7 mM glucose
for 1 hour each (52). For KCl and glibenclamide experiments, islets
were incubated first in 5.6 mM glucose and then 30 mM KCl or 1 μM
glibenclamide (Sigma-Aldrich). A Rat/Mouse Insulin ELISA kit (Mil-
lipore) was used to measure the insulin levels in media.

Calcium imaging of islets. Hand-picked islets were loaded with 4
μM Fluo-4 (Invitrogen) in KRB with 20 mM HEPES and 0.1% BSA,
ph 7.4, for 40 minutes and then imaged on a Zeiss LSM 880 confo-
cal microscope (Plan-Apochromat 20x M27, NA0.8 objective) in 2,
5, 8, and 16 mM glucose, with analyses as previously described (53).
Following a 6-minute incubation at each concentration, a 5-minute
time series was acquired, and 20 mM KCl was injected at the end of
acquisition to prime maximum calcium release. Data were analyzed using Imagej
(NIH) and averaged over 20 cells in 6 different islets from each of 4 different mice per genotype. Data are expressed as
fluorescence intensity under each condition relative to basal (non-
treated) conditions.

ROS detection from whole islets or dispersed islet cells. For whole islets,
equivalent numbers of hand-picked islets of each genotype were incu-
bated in media containing 10 μM DHE (Molecular Probes) for 1 hour,
washed with PBS, and mounted. Epifluorescence images were obtained using a Zeiss Axioskop, and DHE fluorescence was quantified in 6 ran-
dom fields per sample using Imagej. For dispersed islets, equivalent numbers of cells from each genotype (pooled from multiple animals)
were plated in RPMI media in 96-well plates overnight, incubated with
10 μM DHE or 10 μM H2DCFDA (DCF; Molecular Probes) for 1 hour,
and then treated with 100 μM H₂O₂ (Sigma-Aldrich) for 2 hours. Fluo-
rescence was quantified in each well using a TECAN plate reader. To
detect ROS production in low- (3 mM) or high-glucose (20 mM)
conditions, dispersed islets were plated on poly-D-lysine-coated (Sigma-
Aldrich) glass-bottom culture dishes (MatTek Corp.). After overnight
culture, islets were incubated in KRB containing 3 mM or 20 mM glu-
cose with 10 μM DCF for 1 hour at 37°C. Immediately after washing,
fluorescence images were obtained using a Leica DMIRB microscope.
DCF fluorescence of individual islet cells from 8–10 random fields per
condition was quantified using Leica Application Suite AF (19).

Troxol equivalent antioxidant capacity. Antioxidant capacity was
quantified in lysates from hand-picked islets (n = 4 mice/genotype)
as described previously, and values are reported per microgram islet protein (54).

RNAseq analysis of islets. High-quality total RNA (RNA integri-
ty number [RIN] ≥8.5) was prepared from hand-picked islets (n = 4
mice/genotype) using TRIzol reagent, treated with TURBO DNAse
(Thermo Fisher), and used to prepare SeqPlex RNAseq libraries
(Sigma-Aldrich). Sequencing was performed by the Washington
University Genome Technology Access Center using two lanes of
Illumina HiSeq 2500. Reads were demultiplexed and trimmed, and
STAR alignment and quantification analysis were carried out using
the Partek Flow platform. Uniquely aligned reads were quantified to
identify genes with at least a 2-fold change between genotypes, with
P < 0.05 and an FDR step-up of 0.05. Genes identified were further
analyzed for potential U32a, U33, U34, and U35a snoRNA target sites
using the PLEYX program and a cut-off of minimum free energy for
predicted duplexes of less than –20.4 kcal/mol (22). Sequence data are
available in the NCBI’s Gene Expression Omnibus (GEO GSE87354).

Streptozotocin treatment. Eight-week-old female mice were inject-
ed with streptozotocin intraperitoneally (Sigma-Aldrich; 50 mg/kg
in 0.1 M Na citrate, pH 4.5) for 5 consecutive days as previously described
(55). Control animals received buffer only. Serial fasting blood glucose
and body weight were quantified every 2 weeks; GTT was performed
at 8 weeks after the streptozotocin injection, and pancreases were har-
vested for histological analysis.

Intraperitoneal GTT and ITT. In vivo dynamic testing was car-
rried out following a 4-hour fast using standard procedures of the
NIH-sponsored National Mouse Metabolic Phenotyping Centers
with α-Ki-67 antibodies (anti-rabbit monoclonal IgG, 1:200, Cell Signaling Technology 9129), quantified from >75 islets per condition (n = 4 mice [>3,500 nuclei]/genotype/condition). Stained sections were examined using an Olympus FSX100 microscope.

**Morphometry.** Morphometric analysis of pancreases from 8-week-old mice was performed as previously reported (56). For measurement of β cell mass, every 40th pancreatic section was immunostained with guinea pig anti-insulin antibody (1:100, Invitrogen) and counterstained with hematoxylin. The β cell mass for each mouse was quantified using Image Pro Plus software (Media Cybernetics) by obtaining the fraction of the cross-sectional area of pancreatic tissue (exocrine and endocrine) positive for insulin staining and then multiplying by the pancreatic weight.

**Isolation of MEFs and ROS detection.** MEFs were harvested from embryos at E13.5 and cultured in DMEM with 10% FBS, 2 mM (http://www.mmpc.org/shared/protocols.aspx). Mice were injected intraperitoneally with 1 g/kg glucose (GTT) or 1 U/kg insulin (ITT). Blood glucose was measured at 0, 15, 30, 60, and 120 minutes after the injection using a glucometer (Contour). Serum was analyzed for insulin at 0 and 30 minutes of GTT at the Washington University Diabetes Research Center Immunoassay Core by a sensitive Singulex single molecule tracking method that has a lower limit of quantification of 19 pg/ml.

**Histological and immunofluorescence analyses.** For histological analyses, 5-μm sections of formalin-fixed, paraffin-embedded pancreas tissues were stained with H&E. For TUNEL, sections were labeled with TUNEL reagent (Cell Death Detection Kit TMR, Roche), followed by overnight incubation with α-insulin antibodies (polyclonal guinea pig antibody, 1:200, Dako IR002). TUNEL-positive signals were quantified from >75 islets per condition (n = 4 mice [>5,000 nuclei]/genotype/condition). Proliferation was analyzed with α-Ki-67 antibodies (anti-rabbit monoclonal IgG, 1:200, Cell Signaling Technology 9129), quantified from >75 islets per condition (n = 4 mice [>3,500 nuclei]/genotype/condition).

**Figure 7.** *Rpl13a*-snoless mice are resistant to diabetogenic stimuli. (A–E) streptozotocin- (STZ-) or vehicle-treated (control) 8-week-old WT and –/– mice. (A) Mean fasting blood glucose over time (+SEM) for n = 9 mice per genotype/treatment. (B) Mean blood glucose (+SEM) during GTT at 16 weeks for n = 9 mice per genotype/treatment. (C) Representative pancreas sections stained for 4-hydroxynonenal 5 days after STZ. Scale bar: 25 μm (n = 4 mice per genotype/treatment). (D) Pancreas tissue triol 5 days after STZ for n = 7 mice per genotype/treatment. (E) Representative pancreas sections stained for TUNEL 5 days after STZ. Scale bar: 25 μm. Quantification for n = 4 mice per genotype/treatment. Magnification ×2. (F) Ins2C96Y Akita allele bred into *Rpl13a*-snoless model. Mean (+SEM) random blood glucose at indicated time points for a minimum of n = 7 per group. (G) *Rpl13a*-snoless alleles were bred into the NOD model. Diabetes-free survival over 24 weeks for NOD (n = 26) vs. NOD *Rpl13a*-snoless (n = 16) female mice. *P < 0.05 for (–/–, STZ) vs. (WT, STZ); **P < 0.05 for (WT, STZ) vs. (WT); †P < 0.005 for (–/–, C96Y) vs. (WT, C96Y) vs. (WT); §P < 0.0005 for (–/–, C96Y) vs. (WT); determined by unpaired t test. #P < 0.04 by log-rank testing.
l-glutamine, 1x MEM non-essential amino acids, and 150 μM monothioglycerol. ROS was quantified in low-passage (≤5) MEFs by staining with 10 μM DCF or 5 μM MitoSOX Red (Life Technologies) for 5 minutes in PBS with Ca²⁺/Mg²⁺. Fluorescence intensity was quantified by flow cytometry (BD FACSCalibur), measuring mean signal intensity for 10⁴ events in each sample, and normalized to WT cells.

**Oxidative tissue damage.** Formalin-fixed pancreatic sections were costained for insulin (polycyaline guinea pig antibody, 1:200, Dako) and hydroxyronenol (rabbit polyclonal, 1:100, Abcam) using appropriate Alexa Fluor–coupled secondary antibodies (Molecular Probes). Triol was quantified per mg pancreas tissue and is reported per mg protein (57).

**Mitochondrial DNA copy number.** Relative mitochondrial DNA content was measured from isolated islets using RT-qPCR and nuclear DNA content as an internal control, as described previously (58).

**OCR.** Oxygen consumption of islets was measured using a Seahorse XF24 analyzer (Seahorse Bioscience) (15). Fifty islets were hand picked and washed once in assay media containing 1% FBS and 1 mM l-glutamine, and 3 mM or 20 mM glucose, and then transferred into the depressed well of an XF24 Islet Capture Microplate. OCR was measured at basal glucose levels, as well as with drugs acting on the respiratory chain: oligomycin (ATP synthase inhibitor; 5 μM), FCCP (uncoupler; 7.5 μM), rotenone (complex I inhibitor; 0.1 μM), and antimycin A (complex III inhibitor; 1 μM) — all from Sigma-Aldrich. After the assays, the islets were washed once with PBS, and protein was quantified by microBCA assay (Pierce).

**Electron microscopy.** Islets were fixed in a modified Karnovsky’s fixative of 3% glutaraldehyde, 1% paraformaldehyde in 0.1 M sodium cacodylate buffer; post-fixed in 2% osmium tetroxide in 0.1 M sodium cacodylate buffer; stained with 2% aqueous uranyl acetate for 30 minutes; dehydrated in graded acetone; and embedded in Poly/Bed 812 (Polysciences Inc.). 90-nm sections were examined by a JEOL model 1200EX electron microscope. Digital images were acquired using the AMT Advantage HR (Advanced Microscopy Technology) high-definition CCD, 1.5 megapixel TEM camera.

**Statistics.** Results are presented as mean ± SEM for a minimum of 3 independent experiments. Statistical significance was assessed by 2-tailed Student’s t test or log-rank test. P < 0.05 was considered significant. Serial glucose and GTT for streptozotocin-treated WT and knock-out mice (Figure 7) were compared using multiple unpaired t tests and corrected for multiple comparisons using the Sidák-Bonferroni method, with α of 0.05.

**Study approval.** Animal studies were approved by the Institutional Animal Care and Use Committee of Washington University in St. Louis.

**Author contributions**

JL and JES designed the study in consultation with FU, MSR, DWP, and DSO. Experiments were performed by JL, ANH, CLH, JM, KDP, ZL, DES, HF, RS, JZ, and SCCH. The manuscript was written by JL and JES. All authors contributed to editing the manuscript and support the conclusions.

**Acknowledgments**

This work was supported by NIH 2 R01 DK064989, Fondation Leducq 12CVD04, the Juvenile Diabetes Research Foundation (1-IN0-2014-179-A-V), and the American Diabetes Association (7-09-CVD-07) to JES; by NIH R01 DK098584 (to MSR); and by the Washington University Diabetes Research Center (Transgenic and ES Cell, Morphology and Metabolic Analysis, Immunoassay, Diabetes Models Phenotyping, Mass Spectrometry, and Immunology of Type 1 Diabetes Cores; P30 DK020579). Calcium imaging was performed at the Washington University Center for Cellular Imaging. We thank the Genome Technology Access Center in the Department of Genetics at Washington University School of Medicine for help with RNAseq analyses. The Center is partially supported by an NCI Cancer Center Support grant to the Siteman Cancer Center (NIH P30 CA91842) and by the Washington University Institute of Clinical and Translational Sciences/Clinical & Translational Science Award (ICTS/CTSA) (NIH ULI TR000448).

Address correspondence to: Jean E. Schafer, 660 South Euclid Avenue, Campus Box 8086, St Louis, Missouri 63110, USA. Phone: 314.362.8717; E-mail: jschafer@wustl.edu.